Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2023 Annual Meeting | C132 - Controversies in Stroke Treatment and Prevention

Tuesday 04/25/23
01:00 PM - 03:00 PM EST Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Pierre Fayad, MD, FAAN, FAHA
Cerebrovascular Disease and Interventional Neurology
Participants should become familiar with areas in stroke treatment and prevention where evidence is lacking or insufficient to formulate clear recommendations, or where new evidence has emerged that challenges the current consensus. The course will address thoroughly a selected group of such controversial areas, that have not been covered in this previous course, and provide attendees with practical approaches to help them sort through such situations.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student, Business Administrator
Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM EST Introduction Overview of Session
Pierre Fayad, MD, FAAN, FAHA
01:05 PM - 01:35 PM EST Speaker Controversies in the Diagnosis and Management of Intracerebral Hemorrhage
Steven M. Greenberg, MD, PhD, FAAN
01:35 PM - 02:05 PM EST Speaker Controversies in the Management of Hyperlipidemia For Stroke Prevention
Larry B. Goldstein, MD, FAAN, FAHA
02:05 PM - 02:35 PM EST Speaker Controversies in Anti-Thrombotic Therapy for Acute Stroke and Prevention
Pierre Fayad, MD, FAAN, FAHA
02:35 PM - 03:00 PM EST Discussion Panel Discussion and Questions and Answers
Pierre Fayad, MD, FAAN, FAHA, Steven M. Greenberg, MD, PhD, FAAN, Larry B. Goldstein, MD, FAAN, FAHA
Faculty Disclosures
Larry B. Goldstein, MD, FAAN, FAHA The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from CDC. Dr. Goldstein has received publishing royalties from a publication relating to health care.
Pierre Fayad, MD, FAAN, FAHA Dr. Fayad has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Fayad has received personal compensation in the range of $0-$499 for serving as a Member Data Safety & Monitoring Committee with NINDS.
Steven M. Greenberg, MD, PhD, FAAN Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Washington University/IQVIA. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care.